DE69322860D1 - Antikörper gegen alpha v beta 3 integrin - Google Patents

Antikörper gegen alpha v beta 3 integrin

Info

Publication number
DE69322860D1
DE69322860D1 DE69322860T DE69322860T DE69322860D1 DE 69322860 D1 DE69322860 D1 DE 69322860D1 DE 69322860 T DE69322860 T DE 69322860T DE 69322860 T DE69322860 T DE 69322860T DE 69322860 D1 DE69322860 D1 DE 69322860D1
Authority
DE
Germany
Prior art keywords
integrin
pct
beta
sec
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69322860T
Other languages
English (en)
Other versions
DE69322860T2 (de
Inventor
Kyung Kim
Sarah C Bodary
Anan Chuntharapai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69322860D1 publication Critical patent/DE69322860D1/de
Application granted granted Critical
Publication of DE69322860T2 publication Critical patent/DE69322860T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
DE69322860T 1992-04-03 1993-03-30 Antikörper gegen alpha v beta 3 integrin Expired - Lifetime DE69322860T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86267992A 1992-04-03 1992-04-03
US2591393A 1993-03-03 1993-03-03
PCT/US1993/002987 WO1993020229A1 (en) 1992-04-03 1993-03-30 ANTIBODIES TO ALPHAvBETA3 INTEGRIN

Publications (2)

Publication Number Publication Date
DE69322860D1 true DE69322860D1 (de) 1999-02-11
DE69322860T2 DE69322860T2 (de) 1999-07-01

Family

ID=26700459

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69322860T Expired - Lifetime DE69322860T2 (de) 1992-04-03 1993-03-30 Antikörper gegen alpha v beta 3 integrin

Country Status (8)

Country Link
US (5) US5578704A (de)
EP (1) EP0633945B1 (de)
JP (1) JP3353209B2 (de)
AT (1) ATE175241T1 (de)
AU (1) AU680411B2 (de)
CA (1) CA2132091C (de)
DE (1) DE69322860T2 (de)
WO (1) WO1993020229A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
US7150974B1 (en) 1991-04-05 2006-12-19 The General Hospital Corporation Parathyroid hormone receptor binding method
JP3464796B2 (ja) * 1991-04-05 2003-11-10 ザ ジェネラル ホスピタル コーポレーション 副甲状腺ホルモンのレセプターとそれをコードしているｄｎａ
US7132260B2 (en) * 1991-04-05 2006-11-07 The General Hospital Corporation DNA encoding parathyroid hormone receptor
EP0677060A1 (de) * 1993-01-08 1995-10-18 Tanabe Seiyaku Co., Ltd. Die Zell-Adhäsion hemmende Peptide
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
JP2000516201A (ja) 1996-05-31 2000-12-05 ザ スクリップス リサーチ インスティテュート 血管形成阻害方法及び血管形成阻害に有用な組成物
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US20010011125A1 (en) * 1997-01-30 2001-08-02 William D. Huse Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
EP1491632A3 (de) * 1997-03-12 2006-01-04 Smithkline Beecham Corporation Anti-alphavbeta3 humanizierte monoklonale Antikörper
EP0973550B1 (de) * 1997-04-11 2002-10-09 G.D. SEARLE & CO. Antagonistische anti-avb3 integrin antikörper
AU6954498A (en) * 1997-04-11 1998-11-11 G.D. Searle & Co. Methods for using antagonistic anti-avb3 integrin antibodies
US6210904B1 (en) * 1997-10-14 2001-04-03 Merck & Co., Inc. Anticoagulant test
DE19828068C2 (de) * 1998-06-24 2003-12-18 Peter Dietsch Mittel zur spezifischen Hemmung osteoklastärer Knochenresorption
WO2000009143A1 (en) * 1998-08-13 2000-02-24 G.D. Searle & Co. Multivalent avb3 and metastasis-associated receptor ligands
NZ511937A (en) * 1998-12-04 2004-02-27 Novartis Ag Methods and compositions for targeting an activated vitronectin receptor with a ligand comprising adenovirus-2 penton base or fragment thereof
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6159443A (en) * 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
US7049140B1 (en) 1999-04-29 2006-05-23 Vanderbilt University X-ray guided drug delivery
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6037176A (en) * 1999-06-25 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of integrin beta 3 expression
ATE438413T1 (de) * 1999-09-08 2009-08-15 Markus Albers Integrin-vermittelte arzneimittel-zielrichtung
DE50002293D1 (de) * 1999-10-28 2003-06-26 Hofbauer Reinhold Verwendung von csf-1-inhibitoren
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
AU6595301A (en) * 2000-05-12 2001-11-20 Vlaams Interuniv Inst Biotech Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7220824B1 (en) 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219305A1 (de) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Konjugate von Integrinrezeptorantagonisten und einem zytostatischen Mittel mit spezifisch spaltbaren Linkergruppen
NZ528076A (en) * 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
EP1487492A4 (de) * 2002-03-04 2008-10-01 Medimmune Inc Prävention oder behandlung von krebs mit integrin alphavbeta3 antagonisten in kombination mit anderen mitteln
US20050084489A1 (en) * 2002-03-04 2005-04-21 Wilder Ronald L. Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
EP2270049A3 (de) 2002-04-12 2011-03-09 Medimmune, Inc. Rekombinante Anti-Interleukin-9-Antikörper
EP1517704A1 (de) * 2002-06-28 2005-03-30 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Verwendung von antikörpern gegen flt1 zur behandlung von osteoporose
US20050186204A1 (en) * 2002-06-28 2005-08-25 Peter Carmeliet Use of antibodies against FLT-1 for the treatment of osteoporosis
JP2006516635A (ja) * 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストの使用
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20070185077A1 (en) * 2003-07-15 2007-08-09 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
DK1755660T3 (da) * 2004-05-07 2010-07-19 Univ North Carolina Fremgangsmåde til forbedring eller hæmning af insulin-lignende vækstfaktor-I
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
RU2384345C2 (ru) 2004-06-04 2010-03-20 Дженентек, Инк. Способ лечения рассеянного склероза
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006099698A2 (en) 2005-03-24 2006-09-28 Thromb-X N.V. Novel anti-plgf antibody
EP1904095B1 (de) * 2005-06-30 2013-05-29 VIB, vzw Behandlung von leberzirrhose und ihre komplikationen
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
WO2008008373A2 (en) 2006-07-11 2008-01-17 Arubor Corp Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
EP2079483A4 (de) * 2006-07-29 2010-10-20 Robert Lamar Bjork Jr Bispezifische monoklonale antikörper (spezifisch für cd3 und cd11b)-therapeutische arzneimittelsysteme
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
JP5522717B2 (ja) * 2008-09-19 2014-06-18 国立大学法人佐賀大学 アトピー性皮膚炎の検出方法および予防・治療剤のスクリーニング方法
ES2592902T3 (es) 2008-10-02 2016-12-02 Vib Vzw Inhibición del PlGF para el tratamiento de la leucemia positiva para el cromosoma Filadelfia
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP2012513589A (ja) * 2008-12-23 2012-06-14 ジーイー・ヘルスケア・リミテッド 骨髄イメージング剤としての９９ｍＴｃ−ペプチド系化合物の応用
EP3939617A1 (de) 2009-02-13 2022-01-19 Immunomedics, Inc. Konjugate mit einer intrazellulär spaltbaren bindung
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
IN2012DN03354A (de) 2009-12-02 2015-10-23 Immunomedics Inc
CN107115526A (zh) 2011-05-02 2017-09-01 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
DK2785739T3 (en) 2011-12-01 2017-07-03 Thrombogenics Nv IMPROVING THE RESULT OF TREASURE CULECTOMY
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN104768975A (zh) * 2012-08-31 2015-07-08 北卡罗来纳大学教堂山分校 用于增强或抑制胰岛素-样生长因子1(igf-1)的单克隆抗体
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
MX2016010683A (es) 2014-02-21 2017-05-11 Ibc Pharmaceuticals Inc Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
EP3172222A4 (de) 2014-07-24 2018-03-21 Washington University Gegen strahlungsinduzierte moleküle gerichtete zusammensetzungen und verfahren zur verwendung davon
CN106999517A (zh) 2014-10-07 2017-08-01 免疫医疗公司 抗体‑药物缀合物的新辅助剂用途
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
PL3313443T3 (pl) 2015-06-25 2023-11-06 Immunomedics, Inc. Łączenie przeciwciał anty-hla-dr lub anty-trop-2 z inhibitorami mikrotubuli, inhibitorami parp, 5 inhibitorami kinazy brutona lub inhibitorami 3-kinazy fosfoinozytydu istotnie poprawia wynik terapeutyczny nowotworu
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
EP3359572A2 (de) 2015-10-06 2018-08-15 H. Hoffnabb-La Roche Ag Verfahren zur behandlung von multipler sklerose
EP3207937A1 (de) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland Verfahren zur behandlung oder prävention von sepsis
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
CN113557246B (zh) * 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
WO2022157336A1 (en) 2021-01-22 2022-07-28 Royal College Of Surgeons In Ireland Treatment of coronavirus
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US5306620A (en) * 1987-07-08 1994-04-26 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
JPH02502156A (ja) * 1987-11-19 1990-07-19 スクリップス　クリニック　アンド　リサーチ　ファウンデーション 内皮細胞のｒｇｄ指向粘着レセプターに対するモノクローナル抗体
US5057604A (en) * 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites

Also Published As

Publication number Publication date
EP0633945B1 (de) 1998-12-30
WO1993020229A1 (en) 1993-10-14
CA2132091A1 (en) 1993-10-14
AU3941393A (en) 1993-11-08
US6359126B1 (en) 2002-03-19
US5578704A (en) 1996-11-26
CA2132091C (en) 2008-09-16
US6369204B1 (en) 2002-04-09
US5652110A (en) 1997-07-29
AU680411B2 (en) 1997-07-31
US5652109A (en) 1997-07-29
JPH07505528A (ja) 1995-06-22
JP3353209B2 (ja) 2002-12-03
ATE175241T1 (de) 1999-01-15
DE69322860T2 (de) 1999-07-01
EP0633945A1 (de) 1995-01-18

Similar Documents

Publication Publication Date Title
DE69322860T2 (de) Antikörper gegen alpha v beta 3 integrin
DE69321218D1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
ATE117434T1 (de) Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
ATE157990T1 (de) Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung
DE69328550T2 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
DE69026615T2 (de) Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest
DK0654085T3 (da) Monomere og dimere antistof-fragment-fusionsproteiner
FI944509A (fi) Interferonireseptorin vastaisia monoklonaalisia vasta-aineita, joilla on neutralisoivaa aktiivisuutta tyypin I interferonia vastaan
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
NO976122D0 (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
ES2070488T5 (es) Procedimiento para la diagnosis de enfermedades tumorales.
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
KR890008313A (ko) 안티 pci모노클론 항체
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
FI86255B (fi) Monoklonal antiurokinase-antikropp, den innehaollande matris och biokemiska testpackningar, i vilka den anvaendes.
ATE209359T1 (de) Bestimmung von freiem und komplexiertem trypsinogen-2
DE69126302D1 (de) Monoklonaler antikörper gegen herzglykosid und dessen verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition